NASDAQ:INDI

Indie Semiconductor (INDI) Stock Rockets to New Highs on Q2 Beat and AI Tech Wins

Indie Semiconductor shares surged 19% to a 52-week high of $5.58 on Oct. 14, closing at $5.56 after heavy trading. Q2 revenue reached $51.6M, beating consensus, with non-GAAP EPS of –$0.08 in line. Indie plans to acquire Vienna’s emotion3D for $20M plus up to $10M in earnouts, with closing expected in Q4. The company also unveiled a new GaN visible-laser for quantum computing and automotive LiDAR.

15 October 2025

Earnings Reports·NASDAQ:INDI·Stock Market·Technology

Mixed-Signal and RF Components: June–July 2025 Industry Report

Mixed-Signal Devices launched the MS4022 RF synthesizer on June 16, generating 675 MHz–22 GHz with 25 fs RMS phase jitter. Falcomm and GlobalFoundries reported 50% PAE in a 13 GHz CMOS power amp. 3GPP finalized Release 20 for early 6G research on June 18. The U.S. lifted EDA tool export restrictions for China on July 3, restoring access to Synopsys, Cadence, and Siemens.

9 July 2025

LSE:BA.·NASDAQ:ADI·NASDAQ:CDNS·NASDAQ:INDI·NASDAQ:QRVO·NASDAQ:SNPS·NASDAQ:TSEM·Semiconductors·XETRA:SIE

Regeneus Ltd (RGS.AX) Jumps 33% on Heavy Volume, Signals Short-Term Upside
March 19, 2026, 10:42 PM EDT. Regeneus Ltd (RGS.AX) surged 33.33% to A$0.012 on March 20, 2026, driven by unusually heavy volume of 4.28 million shares, nearly seven times the average. The stock broke above its 50-day and 200-day moving averages, indicating increased short-term trader interest in this clinical-stage biotech focused on osteoarthritis and wound healing. Despite negative earnings per share and liquidity constraints, the price action reflects momentum trading in a volatile sector. Traders should watch intraday support at A$0.010 and resistance near the year high of A$0.020. With a Meyka AI rating of 64.90 (Grade B), the stock is rated HOLD amid high volatility and thin order books typical of small-cap biotechs on the Australian Securities Exchange (ASX).